Psoriasin (S100A7) is increased in the serum of patients with moderate‐to‐severe psoriasis

Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis

(2018) S. M. Awad et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Advanced Glycation End Products in the Pathogenesis of Psoriasis

(2017) Anastasia Papagrigoraki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Psoriasin (S100A7) promotes stress-induced angiogenesis

(2016) J. Vegfors et al.   BRITISH JOURNAL OF DERMATOLOGY

Leukocyte-derived koebnerisin (S100A15) and psoriasin (S100A7) are systemic mediators of inflammation in psoriasis

(2015) Aleksandra Batycka-Baran et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Psoriasin: A Novel Marker Linked Obesity with Psoriasis

(2013) Ragaa H. M. Salama et al.   DISEASE MARKERS

Serum levels of antimicrobial peptides and proteins do not correlate with psoriasis severity and are increased after treatment with fumaric acid esters

(2012) T. Gambichler et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Detection of psoriasin/S100A7 in the sera of patients with psoriasis

(2009) K.S. Anderson et al.   BRITISH JOURNAL OF DERMATOLOGY